Glenn Reicin Quotations

Simply put, engineers were making decisions that senior management and physicians should have made.

Given that the longer-term outlook for CRM is strong and the fact that underlying growth in most other businesses is unchanged, we remain optimistic about the future. As such, we view this quarter as a test of faith.

If the company can expand this agreement to other markets, the opportunity could be big.

We suspect that J&J will continue to pursue acquisitions, but none as large as Guidant.

J&J needs Guidant's deep middle-management bench and the cooperation of senior management.

Overall, we found results in the quarter to be generally weak, but believe the strong market reaction was justified given the anticipated completion of the Guidant vascular acquisition.

The proposed changes ... related to cardiac procedures are dramatic.

We view this as a relatively uneventful quarter for Abbott.

We believe it will be critical for BSX to carefully manage its interaction with the FDA.

The opportunity to expand into other markets could be significant.

We think it is unlikely that these changes will modify purchasing and demand characteristics of medical devices. Hospitals have traditionally had little leverage in reducing device costs.

We think investors will look past third-quarter guidance, as the company has historically been overly conservative, and react favorably to the quarter.

Boston Scientific still has much 'wood to chop' regarding the recovery of the company's cardiac rhythm management business...That said, we believe earnings power for businesses remain substantial.

Greater clarity regarding this transaction and future growth goals (without the Guidant acquisition) are needed,

The device replacements will cause companies to forgo revenue producing replacement units in future years.